Reaction
Intestinal Fistula reporting signals
As of the last recalculation, Intestinal Fistula appears in 1,393 FAERS reports alongside 16 co-occurring drug terms. The strongest observed disproportionality signal is AZATHIOPRINE (PRR 25.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Azathioprine | 136 | 25.5 | 25.5 |
| Vedolizumab | 128 | 24.3 | 24.4 |
| Adalimumab | 631 | 23.5 | 23.6 |
| Mesalamine | 64 | 17.8 | 17.8 |
| Teduglutide | 14 | 15.7 | 15.7 |
| Adalimumab-Fkjp | 47 | 15.7 | 15.7 |
| Adalimumab-Aaty | 47 | 15.3 | 15.3 |
| Adalimumab-Adaz | 50 | 14.6 | 14.7 |
| Infliximab-Dyyb | 27 | 14.1 | 14.1 |
| Mercaptopurine | 14 | 12.2 | 12.2 |
| Regorafenib | 9 | 11.7 | 11.7 |
| Infliximab | 152 | 11.6 | 11.6 |
| Ustekinumab | 64 | 9.7 | 9.8 |
| Isotretinoin | 20 | 6.1 | 6.1 |
| Irinotecan Hydrochloride | 5 | 5.8 | 5.8 |
| Risankizumab-Rzaa | 27 | 5.0 | 5.0 |